Compare MRNA & CI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | CI |
|---|---|---|
| Founded | 2010 | 1792 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2B | 78.3B |
| IPO Year | 2018 | 2018 |
| Metric | MRNA | CI |
|---|---|---|
| Price | $196.25 | $272.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 24 |
| Target Price | $164.53 | ★ $344.40 |
| AVG Volume (30 Days) | ★ 11.3M | 1.6M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.29% |
| EPS Growth | 21.77 | ★ 83.00 |
| EPS | N/A | ★ 18.02 |
| Revenue | $19,263,000,000.00 | ★ $274,900,000,000.00 |
| Revenue This Year | $24.09 | $4.99 |
| Revenue Next Year | $11.33 | $3.82 |
| P/E Ratio | ★ N/A | $15.15 |
| Revenue Growth | 4.29 | ★ 11.24 |
| 52 Week Low | $23.55 | $257.85 |
| 52 Week High | $280.80 | $318.05 |
| Indicator | MRNA | CI |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 34.66 |
| Support Level | $181.02 | $267.62 |
| Resistance Level | $254.48 | $274.69 |
| Average True Range (ATR) | 18.33 | 8.91 |
| MACD | -7.45 | -3.60 |
| Stochastic Oscillator | 5.92 | 11.48 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.